Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$75.62
+2.0%		$74.08
$35.64
▼
$80.97
$6.57B0.24654,020 shs894,292 shs
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$97.73
+4.5%		$96.24
$14.89
▼
$115.51
$6.19B-0.34732,971 shs1.05 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$99.02
+1.0%		$107.45
$74.50
▼
$122.20
$6.72B1.97493,640 shs617,730 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+2.16%+3.00%-3.88%+21.35%+107.27%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+59.79%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
+1.46%+2.24%-16.96%+29.32%+527.85%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+1.28%-3.02%-15.10%+1.26%+2.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$75.62
+2.0%		$74.08
$35.64
▼
$80.97
$6.57B0.24654,020 shs894,292 shs
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$15.50
$15.51
$9.20
▼
$15.73
$1.82B0.972.20 million shsN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$97.73
+4.5%		$96.24
$14.89
▼
$115.51
$6.19B-0.34732,971 shs1.05 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$99.02
+1.0%		$107.45
$74.50
▼
$122.20
$6.72B1.97493,640 shs617,730 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+2.16%+3.00%-3.88%+21.35%+107.27%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.00%0.00%0.00%0.00%+59.79%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
+1.46%+2.24%-16.96%+29.32%+527.85%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+1.28%-3.02%-15.10%+1.26%+2.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.73
Moderate Buy$87.7816.08% Upside
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
1.50
ReduceN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$133.0036.09% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.76
Moderate Buy$140.6742.06% Upside

Current Analyst Ratings Breakdown

Latest DVAX, RYTM, CGON, and ORKA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/14/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$133.00
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/28/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$120.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$200.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$165.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,659.15N/AN/A$9.33 per share8.11
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$330.51M5.51$0.16 per share97.88$4.54 per share3.41
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M35.76N/AN/A$2.08 per share47.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)

Latest DVAX, RYTM, CGON, and ORKA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.41
7.62
6.94
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
14288.64 million84.39 millionOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.43 million113.93 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
6866.21 million50.66 millionN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
41468.53 million64.49 millionOptionable

Recent News About These Companies

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Wolfe Research
September 17 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rhythm-pharmaceuticals-nasdaq-rytm-coverage-initiated-by-analysts-at-wolfe-research-2026-09-17/
RBC Capital Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
September 17 at 8:51 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM/pressreleases/4624961/rbc-capital-reaffirms-their-buy-rating-on-rhythm-pharmaceuticals-rytm/
J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)
September 17 at 8:51 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM/pressreleases/4650268/jp-morgan-remains-a-buy-on-rhythm-pharmaceuticals-rytm/
Wolfe Research Initiates Rhythm Pharmaceuticals at Outperform
September 17 at 8:51 AM  |  marketscreener.comM
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 5.3% After Insider Selling
September 17 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31027709
Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated at Leerink Partners
September 16 at 1:56 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025742
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 15 at 4:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4946697-rhythm-pharmaceuticals-inc-rytm-presents-at-morgan-stanley-24th-annual-global-healthcare
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling
September 15 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-rhythm-pharmaceuticals-nasdaq-rytm-trading-down-53-on-insider-selling-2026-09-15/
Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO David Meeker Sells 50,000 Shares
September 15 at 5:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025493
Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells $5,133,500.00 in Stock
September 15 at 4:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rytm-insider-buying-and-selling-2026-09-15/
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) CEO Sells 50,000 Shares of Stock
September 14 at 9:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-rhythm-pharmaceuticals-nasdaq-rytm-ceo-sells-50000-shares-of-stock-2026-09-14/
Rhythm Pharmaceuticals (NASDAQ:RYTM) Now Covered by Analysts at Leerink Partners
September 14 at 12:05 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-rhythm-pharmaceuticals-nasdaq-rytm-now-covered-by-analysts-at-leerink-partners-2026-09-14/
California State Teachers Retirement System Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM
September 14 at 3:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-grows-stock-holdings-in-rhythm-pharmaceuticals-inc-rytm-2026-09-14/
Head-To-Head Survey: Generate Biomedicines (NASDAQ:GENB) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM)
September 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31018102
Rhythm Pharmaceuticals Presents New Data on Setmelanotide Therapy and Phase 3 Analyses At European Society for Paediatric Endocrinology Meeting
September 11, 2026  |  marketscreener.comM
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359459/0/en/rhythm-pharmaceuticals-announces-new-data-presentations-at-the-european-society-for-paediatric-endocrinology-meeting.html
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Brokerages
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31014862
Squarepoint Ops LLC Buys 159,953 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-buys-159953-shares-of-rhythm-pharmaceuticals-inc-rytm-2026-09-09/
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-rhythm-pharmaceuticals-inc-nasdaq-rytm-receives-consensus-rating-of-moderate-buy-from-brokerages-2026-09-05/
43,908 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Legal & General Group Plc
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-43908-shares-in-rhythm-pharmaceuticals-inc-rytm-acquired-by-legal-general-group-plc-2026-09-04/
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Wellington Management Group LLP
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rhythm-pharmaceuticals-inc-rytm-shares-acquired-by-wellington-management-group-llp-2026-09-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$75.62 +1.50 (+2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$75.61 -0.01 (-0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$97.73 +4.18 (+4.47%)
Closing price 04:00 PM Eastern
Extended Trading
$97.74 +0.02 (+0.02%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$99.02 +1.01 (+1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$96.31 -2.71 (-2.74%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas